Elizabeth Plimack, MD, MS, chief of the division of genitourinary medical oncology at Fox Chase Cancer Center, has been appointed the center’s deputy director. In this newly created role, Plimack’s ...

Factors associated with gene mutation testing in United States veterans with metastatic castration-resistant prostate cancer. This is an ASCO Meeting Abstract from the 2022 ASCO Genitourinary Cancers ...

TAMPA, Fla. — Patient-reported outcomes are important indicators of how cancer drugs impact patients’ lives. By assessing the benefits and risks of drugs from a patient’s perspective, scientists and ...

Exploring Spatial-Temporal Changes in 18F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide We assessed the safety and ...

CHATSWORTH, Calif., Feb. 17, 2011 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), at the American Society for Clinical Oncology (ASCO) 2011 Genitourinary Cancers Symposium in Orlando, FL, ...

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced its planned presence at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), including three accepted ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced positive final data for a phase 1 trial sponsored and conducted by the U.S. National Cancer Institute (NCI), including ...

This study validated PROSTOX as predicting radiotherapy-induced genitourinary toxicity, which can be differentiated into acute and chronic with mirSNP-based signatures, in patients with prostate ...

PROEAS graph reporting the different PROEAS scores per category for randomized clinical trials individualized by GU tumor type. Abbreviations: PROEAS: Patient Reported Outcome Endpoint Analysis Score; ...

Flatiron’s high-quality real-world data and innovative artificial intelligence-based extraction are generating novel learnings on treatment safety and patterns for people with genitourinary cancers ...